Thanks to member SammyJo for this information. She states, "Note there are no patients on the panel, so I wrote to BPC and asked how we can get our questions answered. We can send in questions to the experts, you can pick one, or just to the group. You might want to ask what the impact of this Act will be on the trial you were in. Send questions to Michael Stubel mstubel@bipartisanpolicy.or

Listen to it here:
http://bipartisanpolicy.org/events/p...-cell-therapy/

Advancing a New Policy Framework for Regenerative Cell Therapy

WHEN: Tuesday, April 12, 2016 9:30 a.m. to 12:00 p.m. ET
WHERE: Bipartisan Policy Center, 1225 Eye St. NW, Suite 1000, Washington, DC

Cell therapies represent one of the most promising areas for the next generation of groundbreaking treatments in the areas of cardiology, neurology, ophthalmology, and orthopedics. New studies for those with Alzheimers’ disease, Parkinson’s disease, heart disease, diabetes, and cancer are encouraging.

Despite the benefits of these treatments, cell therapies are generally not accessible to patients in the United States. Europe and Japan have outpaced the United States in modernizing their regulatory policies to grant patient access to safe cell therapies. As a result, patients are forced to seek treatment overseas and U.S. companies are increasingly making investments in other parts of the world.

A significant amount of policy activity is now underway to address this problem. Earlier this month, bipartisan, bicameral legislation was introduced to create a new regulatory pathway to bring safe and effective treatments to patients in the United States. The REGROW Act was also discussed during the Senate Health, Education, Labor, and Pensions (HELP) Committee’s third and final mark-up of medical innovation legislation.

The Bipartisan Policy Center and the Regenerative Medicine Foundation will be joined by policymakers, scientific and academic experts, practitioners, and patients to discuss the science and benefits of cell therapy and new policies needed to modernize the U.S. regulatory approach for bringing safe and effective treatments to Americans.